News
Opinion: Retired federal appeals court judges Paul Michel and Kathleen O'Malley say Congress should pass legislation to ...
Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Recent cases show some successes by trademark plaintiffs stating claims for trade dress infringement despite their product being disclosed in a utility patent, at least at the pleadings stage.
1d
InvestorsHub on MSNEvoke Pharma Shares Jump 50% Following Patent Approval for GIMOTIEvoke Pharma Inc (NASDAQ:EVOK) saw its stock soar 50% after the specialty pharma company received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering ...
The MCA has revised equity listing rules via the 2025 amendment. Form LEAP-1 is now mandatory for overseas listings with ...
Candidates will assist with the successful procurement of patent protection for innovative technologies, evaluate the designs of new products, and assist with the evaluation of competitor products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results